| 書目名稱 | Proteasome Inhibitors in Cancer Therapy |
| 編輯 | Julian Adams |
| 視頻video | http://file.papertrans.cn/762/761560/761560.mp4 |
| 概述 | Includes supplementary material: |
| 叢書名稱 | Cancer Drug Discovery and Development |
| 圖書封面 |  |
| 描述 | A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade?) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma. |
| 出版日期 | Book 2004 |
| 關(guān)鍵詞 | AIDS; Antigen; Chemotherapie; apoptosis; diagnostics |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-1-59259-794-9 |
| isbn_softcover | 978-1-61737-452-4 |
| isbn_ebook | 978-1-59259-794-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 |
| issn_series | 2196-9906 |
| copyright | Humana Press 2004 |
|Archiver|手機版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2026-1-21 20:28
發(fā)表于 2025-3-21 16:47:18
